A
Anne M. Stiggelbout
Researcher at Leiden University Medical Center
Publications - 330
Citations - 17621
Anne M. Stiggelbout is an academic researcher from Leiden University Medical Center. The author has contributed to research in topics: Medicine & Breast cancer. The author has an hindex of 67, co-authored 294 publications receiving 15419 citations. Previous affiliations of Anne M. Stiggelbout include Netherlands Cancer Institute & Leiden University.
Papers
More filters
Journal ArticleDOI
The 'utility' of the visual analog scale in medical decision making and technology assessment. Is it an alternative to the time trade-off?
TL;DR: It is found that the relationship existed independently of disease state and health status, for 183 cancer patients, and a power transformation of group mean VAS scores to TTO scores was proposed.
Journal ArticleDOI
Dutch Translation and Psychometric Testing of the 9-Item Shared Decision Making Questionnaire (SDM-Q-9) and Shared Decision Making Questionnaire-Physician Version (SDM-Q-Doc) in Primary and Secondary Care.
Sumayah Rodenburg-Vandenbussche,Arwen H. Pieterse,Pieter M. Kroonenberg,Isabelle Scholl,Trudy van der Weijden,Gre P. M. Luyten,Roy F.P.M. Kruitwagen,Henk den Ouden,Ingrid V. E. Carlier,Irene M. van Vliet,Frans G. Zitman,Anne M. Stiggelbout +11 more
TL;DR: The Dutch SDM-Q-9 and SDM -Q-Doc demonstrate good acceptance and reliability; they correlated as expected with the CPSpost and are suitable for use in Dutch primary and specialised care.
Journal Article
Intramuscular or combined intramuscular/intra-arterial administration of bone marrow mononuclear cells: a clinical trial in patients with advanced limb ischemia.
Van Tongeren Rb,Jaap F. Hamming,Willem E. Fibbe,Van Weel,Frerichs Sj,Anne M. Stiggelbout,van Bockel Jh,Jan H.N. Lindeman +7 more
TL;DR: Both IM and combined IM/IA delivery of autologous BMC are safe, and result in relevant and sustained improvement in a considerable proportion of patients with severe PAD who are not amenable for conventional treatment.
The "Utility" Of The Time Trade-Off Method In Cancer Patiens: Feasibility And Proportional Trade-Off
TL;DR: Results showed the Time Trade-Off method to be feasible in curatively treated patients, though the use of life expectancy posed difficulties in some very old subjects, and many patients were unwilling to trade at all.
Journal ArticleDOI
Clinician and cancer patient views on patient participation in treatment decision-making: a quantitative and qualitative exploration.
TL;DR: Assessment of what role oncologists and cancer patients prefer in deciding about treatment, and how they view patient participation in treatment decision-making concluded that clinicians should acknowledge the legitimacy of patients' values in treatment decisions.